PepGen Secures U.S. Patent for PGN-EDODM1, Advancing Myotonic Dystrophy Type 1 Treatment
核心洞察
PepGen received a U.S. composition of matter patent for PGN-EDODM1, providing exclusivity until the second half of 2042 with potential extension following FDA approval.
The investigational therapy targets myotonic dystrophy type 1 (搜索), a severe neuromuscular disease with no approved therapies addressing its underlying cause.
PGN-EDODM1 utilizes PepGen's proprietary Enhanced Delivery Oligonucleotide platform to restore normal RNA splicing function by liberating the MBNL1 (搜索) protein.
PepGen Inc. has received a significant intellectual property milestone with the issuance of U.S. Patent No. 12,465,646 covering its investigational therapy PGN-EDODM1 for myotonic dystrophy type 1 (搜索) (DM1 (搜索)). The composition of matter patent, issued by the United States Patent and Trademark Office, is expected to provide exclusivity for PGN-EDODM1 in the United States into the second half of 2042, with the possibility of patent term extension following FDA approval.
Novel Approach to Treating Myotonic Dystrophy Type 1
PGN-EDODM1 represents a differentiated therapeutic approach for DM1 (搜索), a severe neuromuscular disease that currently has no approved therapies targeting its underlying cause. The investigational candidate utilizes PepGen's proprietary Enhanced Delivery Oligonucleotide (EDO) platform, incorporating unique peptide and linker chemistry to deliver therapeutic oligonucleotides.
"This patent protection underscores the novelty and differentiation of our peptide-conjugated oligonucleotide candidate, PGN-EDODM1, which is designed to address myotonic dystrophy type 1 (搜索)," said James McArthur, PhD, President and CEO of PepGen. "Expanding our patent portfolio represents an important milestone that supports the long-term clinical and commercial potential of this program."
Mechanism of Action and Therapeutic Advantages
The therapy addresses the deleterious effects of cytosine-uracil-guanine (CUG) repeat expansion in the dystrophia myotonic protein kinase (DMPK (搜索)) transcripts, which sequester MBNL1 (搜索), a key RNA splicing protein. PGN-EDODM1 works by binding to the pathogenic CUG trinucleotide repeat expansion present in the DMPK transcripts and disrupting the binding between the CUG repeat expansion and MBNL1.
This mechanism is designed to restore the normal splicing function of MBNL1 (搜索) while allowing DMPK (搜索) transcripts to continue performing their normal cellular functions. PepGen believes this innovative approach may offer considerable advantages over oligonucleotide modalities that rely on knockdown or degradation of the DMPK transcripts, as it liberates MBNL1 to correct downstream mis-splicing events without eliminating the beneficial functions of DMPK.
Regulatory Recognition and Development Status
The U.S. Food and Drug Administration has recognized the potential of PGN-EDODM1 by granting both Orphan Drug and Fast Track Designations for the treatment of patients with DM1 (搜索). These designations reflect the significant unmet medical need in this patient population and the therapy's potential to address the underlying pathophysiology of the disease.
The newly issued patent complements PepGen's expanding global patent estate, which includes multiple issued and pending patents supporting the company's oligonucleotide therapy platform and pipeline development efforts.